Skip to content
DataLookout
Menu

NCT01484678

Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy

StatusActive, Not Recruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 24 versions: 18 with changes below, 6 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Aug 31, 2026 to Aug 31, 2027 Show 6 more changesShow less
    • Eligibility criteria expanded, about 12 words
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 3 of 3 entries
    • Site details revised at 3 of 3 sites
    • Collaborators: details revised at 1 of 4 entries
    • Publications: details revised at 37 of 38 entries
  2. Notable Primary and study completion dates: Aug 31, 2025 to Aug 31, 2026v23
  3. Minor Site contacts updated at 2 of 3 sites
    • Publications: 33 to 38
    v22
  4. Minor Publications: 23 to 33v21
  5. Minor Primary and study completion dates: Aug 2025 to Aug 31, 2025v20
Show 12 earlier versionsHide 12 earlier versions
  1. Notable Eligibility criteria expanded, about 12 wordsv19 Show 6 more changesShow less
    • Primary endpoints revised (3)
    • Start date: Apr 1, 2021 to Sep 1, 2020
    • Secondary endpoints: 4 to 3
    • Study description shortened, about 13 words
    • Collaborators: 5 to 4
    • Publications: 21 to 23
  2. Notable Trial status: Active, Not Recruiting to Recruitingv18 Show 9 more changesShow less
    • Enrollment target: 200 to 550
    • Primary and study completion dates: Aug 2021 to Aug 2025
    • Start date: May 2010 to Apr 1, 2021
    • Eligibility criteria expanded, about 49 words
    • Primary endpoints: 2 to 3
    • Secondary endpoints: 3 to 4
    • Study description expanded, about 158 words
    • Site details revised at 3 of 3 sites
    • Study arms: 2 to 3
  3. Notable Primary and study completion dates: Apr 2020 to Aug 2021
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    • Publications: 11 to 21
    v17
  4. Minor Enrollment target: 185 to 200v13
  5. Notable Trial status: Active, Not Recruiting to Recruitingv9 Show 5 more changesShow less
    • Eligibility criteria shortened, about 18 words
    • Primary endpoints revised (2)
    • Study sites: 4 to 3
    • Secondary endpoints revised (3)
    • Study description expanded, about 5 words
  6. Notable Primary and study completion dates: Apr 2015 to Apr 2020v8 Show 4 more changesShow less
    • Primary endpoints revised (2)
    • Enrollment target: 150 to 185
    • Secondary endpoints revised (3)
    • Publications: 9 to 11
  7. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 4 of 4 sites
    • Publications: 7 to 9
    v7
  8. Minor Publications: 6 to 7v6
  9. Minor Site contacts updated at 1 of 4 sites
    • Publications: 4 to 6
    v5
  10. Minor Publications: 3 to 4v4
  11. Minor Primary completion date: Apr 2015v3
  12. Minor Site contacts updated at 1 of 4 sitesv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from baseline in intramuscular lipid up to 3-10 years
Timeframe: Change in baseline up to 3-10 years
Change from baseline in muscle T2 up to 3 months in DMD
Timeframe: Change in baseline up to 3 months
Correlation between MR measures of intramuscular lipid, functional endpoints and histological markers.
Timeframe: Through study completion, an average of 1 year

Secondary (3)

Change from baseline in muscle T2 up to 5-10 years
Change from baseline in muscle contractile area up to 5-10 years
Change from baseline in muscle T2 at 6 months

Arms and interventions

Age Matched Controls

Age matched non-affected (non-DMD) boys \* This arm is full Age matched non-affected men, matched for men with Becker MD \*Recruiting

Boys/Men with DMD

This group will include ambulatory and non-ambulatory boys/men with Duchenne Muscular Dystrophy ranging from 5-30 years old. \*Recruiting

Adults with Becker MD

This group will include ambulatory and non-ambulatory men with Becker Muscular Dystrophy ranging from 18-62 years old. \* Recruiting

Sites

3 sites in 1 country